Fragmento

Bibliografía obtenida en la búsqueda sistemática • Achiron A. Complications of intravenous immune globulin treatment neurologic disease. Neurology 1997; 49: 899-900. • Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50: 398-402. • Achiron A, Kishner I, Sarove-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 2004; 61: 1515-1520. • Ahn SY, Kim DS. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate. Scand J Rheumatol 2005; 34: 136-139. • Allos BM. Association between Campylobacter infection and Guillain-Barre syndrome. J Infect Dis 1997; 176 Suppl: S125-S128. • Anonymous. Plasma exchange in Guillain-Barre syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol 1992; 32: 94-97. • Anonymous. Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Guillain-Barre Syndrome Steroid Trial Group. Lancet 1993; 341: 586-590. Anonymous. Treatment of Guillain-Barre syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. The Dutch Gillain-Barre Study Group. Ann Neurol 1994; 35: 749-752. PARA ESTA INFORMACIÓN, SUGERIMOS DESCARGAR FORMATO PDF.

Palabras clave: Inmunoglobulina intravenosa (IgIV) enfermedades del sistema nervioso central y periférico.

2007-06-11   |   711 visitas   |   Evalua este artículo 0 valoraciones

Vol. 23 Núm.1. Marzo 2007 Pags. S 22 Acta Neurol Colomb 2007; 23(Sup. 1:1)